NextGen Jane, an Oakland, CA-based reproductive health technology company, raised $9M in Series A funding round.
The round was led by Material Impact, with participation from Access Industries, Viking Global Investors, Liminal Ventures, and several notable angels, including:
– Rox Anderson, MD (Massachusetts General Hospital),
– George Church, Ph.D. (Harvard Medical School),
– Kacey Fitzpatrick, Frances Frei, Ph.D. (Harvard Business School),
– Deborah Kilpatrick, Ph.D.,
– Angela MacFarlane, J.D.,
– Anne Morriss, MBA, Steve Quake, Ph.D. (Stanford University),
– David Walt, Ph.D. (Harvard Medical School) and
– George Whitesides, Ph.D. (Harvard University).
The company plans to use the financing to further advance its scientific data set in select reproductive health areas, positioning it for commercialization sometime in 2020.
Led by Ridhi Tariyal, co-founder and CEO, NextGen Jane is a data-driven health company for women and people who menstruate to engage with and access healthcare. Its smart tampon platform allows users to collect menstrual and cervicovaginal samples with an everyday household product, preserve nucleic acids and other analytes important for disease detection and ship them off to a lab for in-depth sequencing analysis and disease detection. The system allows for preservation of DNA and RNA of cells from the endometrium, cervix, fallopian tubes and ovaries.